Topical Application of Aprepitant Inhibits Erlotinib-Induced Facial Dermatitis and Hair Loss
January 2024
in “
Journal of dermatology and skin science
”
Studysummary In this study, researchers found that applying topical aprepitant, which blocks substance P receptors, significantly reduced facial dermatitis and hair loss in rats experiencing erlotinib-induced skin side effects, highlighting the neurogenic inflammation's role and the protective effect of ROS inhibition.
Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
Read the full study on dermatoljournal.com →